Eli Lilly's retatrutide beats Ozempic in diabetes trials

Statements (6)

1. ● Neutral

   Lilly's retatrutide drug achieved a triple-G result in a diabetes trial, surpassing Novo's Ozempic on blood sugar and weight loss measures

   biopharmadive.comOct 28, 2026 15:53 UTCHigh importance
2. ▲ Bullish

   Eli Lilly's new obesity drug retatrutida outperformed Ozempic in a direct comparative study.

   valor.globo.comOct 28, 2026 15:37 UTCHigh importance
3. ▲ Bullish

   Eli Lilly's retatrutide drug won a head-to-head study against Novo's Ozempic

   investors.comOct 28, 2026 14:02 UTCHigh importance
4. ▲ Bullish

   Eli Lilly's retatrutide helped adults with type 2 diabetes shed roughly twice as much weight as Ozempic's top dose in a large late-stage trial

   newser.comOct 28, 2026 14:00 UTCHigh importance
5. ▲ Bullish

   Eli Lilly's investigational drug retatrutide was more effective at lowering blood sugar than Novo Nordisk's Ozempic in a large diabetes study

   statnews.comOct 28, 2026 13:42 UTCHigh importance
6. ▲ Bullish

   Eli Lilly's retatrutide demonstrated superior effectiveness in a head-to-head trial against Novo Nordisk's Ozempic for diabetes treatment

   endpoints.newsOct 28, 2026 10:45 UTCHigh importance